WhiteSwell key facts
as of Oct 2026- Operator of a science-driven company intended to improve the treatment of acute decompensated heart failure by leveraging the lymphatic system.
- WhiteSwell is valued at approximately $71.5M as of Oct 2026 (last reported valuation).
- It has raised $30.0M; the latest was Later Stage VC in Feb 2025.
- Notable investors include Enterprise Ireland, RA Capital Management, Western Development Commission, VI Ventures, Abiomed — 8 tracked in total.
- Status: Privately Held (backing).
WhiteSwell's last reported valuation, Dec 2018. Nothing priced has surfaced since.
- ·Watch WhiteSwell: the Monday email on marks, rounds and moves
WhiteSwell funding rounds
No funding rounds for WhiteSwell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
WhiteSwell valuation
WhiteSwell's last reported valuation was $71.5 million in Dec 2018. No priced round, secondary trade or fund mark has surfaced since.
WhiteSwell investors
8 investors are on record for WhiteSwell, including Enterprise Ireland, RA Capital Management, Western Development Commission and VI Ventures.
About WhiteSwell
Operator of a science-driven company intended to improve the treatment of acute decompensated heart failure by leveraging the lymphatic system. The company provides a medical device to create a low-pressure zone at the thoracic duct outlet to reduce resistance to lymphatic drainage and improve clinical outcomes for ADHF patients, enabling the healthcare industry to address the unmet need for effective and safe treatment options for ADHF, a serious condition with high mortality rates.
- Sector
- Healthcare
- HQ
- Galway, Ireland
- Founded
- 2014
- Employees
- 40
- Website
- whiteswell.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.